Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

16.39 -0.01 (-0.06%)
Streaming Delayed Price Updated: 1:12 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 71,610
Open 16.49
Bid (Size) 16.27 (100)
Ask (Size) 16.40 (200)
Prev. Close 16.40
Today's Range 16.23 - 16.64
52wk Range 7.800 - 19.71
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bicara Therapeutics to Participate in Upcoming Investor Conferences
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
From Bicara Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+0.1%
+0.1%
1 Month
-0.2%
-0.2%
3 Month
-13.2%
-13.2%
6 Month
+44.8%
+44.8%
1 Year
+26.3%
+26.3%

More News

Read More
News headline image
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
Via Investor Brand Network
News headline image
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
From BioMedWire
Via GlobeNewswire
News headline image
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Via Investor Brand Network
News headline image
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Via FinancialNewsMedia
News headline image
These stocks that are showing activity before the opening bell on Monday. ↗
Via Chartmill
News headline image
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
4 Biotech Stocks Seeing Explosive Momentum Gains ↗
Via Benzinga
Topics ETFs Stocks
News headline image
Bicara Therapeutics to Participate in Upcoming Investor Conferences
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On? ↗
Via Benzinga
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill

Frequently Asked Questions

Is Bicara Therapeutics Inc. - Common Stock publicly traded?
Yes, Bicara Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Bicara Therapeutics Inc. - Common Stock trade on?
Bicara Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Bicara Therapeutics Inc. - Common Stock?
The ticker symbol for Bicara Therapeutics Inc. - Common Stock is BCAX on the Nasdaq Stock Market
What is the current price of Bicara Therapeutics Inc. - Common Stock?
The current price of Bicara Therapeutics Inc. - Common Stock is 16.39
When was Bicara Therapeutics Inc. - Common Stock last traded?
The last trade of Bicara Therapeutics Inc. - Common Stock was at 02/24/26 01:12 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.